Cyteir Therapeutics Q2 EPS $(4.83) Down From $(3.18) YoY
Cyteir Therapeutics (NASDAQ:CYT) reported quarterly losses of $(4.83) per share. This is a 51.89 percent decrease over losses of $(3.18) per share from the same period last year.
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow.
55 Biggest Movers From Friday
Gainers
IKONICS Corporation (NASDAQ: IKNX) shares surged 64.3% to close at $18.56 on Friday after the company reported a merger deal with TeraWulf.
List Of Initial Public Offerings For Friday, Jun. 18, 2021
AiHuiShou International (RERE)
Century Therapeutics (IPSC)
ATAI Life Sciences (ATAI)
Jaws Juggernaut Acquisition (JUGGU)
Tremor International (TRMR)
Ambrx Biopharma (AMAM)
Cyteir Therapeutics (CYT)
Codex DNA